Inmune Bio, Inc 8-K, filed Dec 9, 2022
Inmune Bio, Inc. (INMB)
About this 8-K
Inmune Bio, Inc filed this 8-K on December 9, 2022, reporting on events of December 8, 2022.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
| (Exact name of registrant as specified in charter) |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||
| of incorporation) | Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Item 8.01. Other Events.
On December 8, 2022, INmune Bio Inc. (the “Company”) issued a press release announcing that will present data from UK patients with MDS or AML treated with INKmune™ at the annual American Society for Hematology (ASH) Conference held in New Orleans December 10th – 13th. A copy of this press release is attached herewith as Exhibit 99.1.
Additionally, the Company is filing as Exhibit 99.2 to this Current Report on Form 8-K a slide deck that the Company intends to use in a presentation.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
| 99.1 | Press Release dated December 8, 2022 | |
| 99.2 | Presentation | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: December 9, 2022 | INMUNE BIO INC. | |
| By: | /s/ David Moss | |
| David Moss | ||
| Chief Financial Officer | ||
2
Exhibit 99.1

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™
Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease will present data from UK patients with MDS or AML treated with INKmune™ at the annual American Society for Hematology (ASH) Conference held in New Orleans December 10th – 13th. The clinical team at Southampton University in the UK, led by Professor Kim Orchard, the past president of the British Society of Blood and Marrow Transplantation and Cellular Therapy, is the first author of the presentation.
The poster presents findings from patients who have received INKmune therapy for treatment of their AML/MDS and provides additional information on the biologic changes that occur in the patients’ NK cells after treatment with INKmune. Highlights include:
| 1. | INKmune safely administered to 4 patients without SAE/R. |
| 2. | Demonstrable and sustained NK activation in 3 of the 4 patients. Patient 4 had a high level of disease with low numbers of NK cells of which more than half her NK cells were immature. |
| 3. | Persistent tumor killing memory-like NK cells in the patient with MDS for more than 100 days. |
| 4. | NK activation temporally associated with significant changes in systemic levels of key cytokines including Macrophage Inflammatory Proteins (MIP1-a and MIP1-b). |
| 5. | INKmune™ activated NK cells show proteomic and metabolomic changes predictive of improved survival in the tumor microenvironment (TME). |
“The treatment of these patients with advanced hematologic malignancies has produced proof-of-concept data for INKmune while expanding insight into the role of NK cells in controlling cancer,” said Dr. Mark Lowdell, CSO of INmune Bio. “The performance of INKmune primed NK cells in vivo has mirrored all of our in vitro data and the proteomics and metabolomics data increase our knowledge into INKmune™ mechanism of action. The increase in circulating MIP1-a and MIP1-b in our patients after INKmune is very exciting. MIP-1 cytokines promote anti-cancer immune responses by intra-tumoral monocytes and T cells and promote recruitment of immune cells into the tumor microenvironment. We believe these new insights will aid in reaching our ultimate goal of providing a more comprehensive therapy for these extremely poor prognosis patients.”
The Laurel Phase I trial continues to enroll patients in the UK and EU with two new sites in the process of opening recruitment. In addition, the Company is preparing to expand the INKmune™ program to the US in a solid tumor indication. The Company will make additional announcements regarding the solid tumor target and the timing of the clinical trial.
“Presentation of data at the most important hematologic cancer meeting is an honor. We hope this will be the first of many presentations on this promising program,” said RJ Tesi, MD, CEO of INmune Bio. “The ability of INKmune™ primed NK cells to survive and thrive in the hypoxic and immunologically hostile TME is unique. This biology makes a pivot to INKmune™ treatment of solid tumors an obvious next step in the platform’s growth.”
About INKmune™
INKmune™ is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals akin to treatment with at least three cytokines in combination. INKmune™ is stable at -80oC and is delivered by a simple IV infusion. The INKmune:NK interaction ligates multiple activating and co-stimulatory molecules on the NK cell and enhances its avidity of binding to tumor cells; notably those resistant to normal NK-mediated lysis. Tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma, ovarian cancer, breast cancer.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO
(858) 964-3720
info@inmunenbio.com
Investor Contact:
Jason Nelson
Core IR
(516) 842-9614 x-823
Exhibit 99.2

Subject Age at Rx Diagnosis Stage at treatment Post INKmune TM L003 78y MDS - EB2 Tri - lineage dysplasia Tri - lineage dysplastic . Failed 16 cycles of Azacytidine . 19% BM blasts , RAD21 VAF 45% Weekly red cell and platelet transfusions ECOG 2. D119 – 13% blasts , RAD21 VAF 38% Plt independent , red cell transfusions every two weeks , no infections nor admissions . ECOG 0 C01 19y AML Congenital GATA2 mutation . Relapsed post 3x allo - HSCT. 8 months as in - patient with cytopenias , blood product dependent and infections . Stabilised counts at 2 months , reduced bone pain , neutrophil recovery and discharged home. Disease recurrence at 6 months and died . C02 24y AML - M6 Relapsed post 2x haplo m/m HSCT – 5% blasts Counts stabilised for 4 months allowing discharge to home. Bridged to third allo HSCT C03 17y MDS - EB2 Tri - lineage dysplasia Relapsed AML post 2nd allo HSCT. In CR post salvage chemotherapy . D127 – relapsed AML. On salvage chemotherapy . Natural killer (NK) cells can have memory - like functions ( mlNK ) . Priming of NK cells with the tumour cell product, INKmune TM generates tumour - induced mlNK (TIML - NK) cells with enhanced cytokine production and cytotoxicity against multiple NK - resistant tumour target cell lines [ 1 , 2 , 3 , 4 , 5 ] . P roteomic profiling of TIML - NK showed increases of proteins promoting mitochondrial survival and function, whilst sparing mitochondrial damage typically associated with cytokine - mediated activation . INKmune priming increased NK metabolism whilst enhancing mitochondrial respiratory capacity and maintaining the glycolytic reserve depleted by cytokine activation . We have treated four patients with advanced MDS or multiply relapsed AML with INKmune TM with absence of adverse effects despite marked increases in systemic cytokines and development of persistent activated, ml - NK cells with enhanced lytic function . 1. To determine whether in vivo exposure of resting NK cells ( rNK ) to replication - incompetent INB16 ( INKmune TM ) can activate NK cells and generate a memory - like phenotype 2. To investigate the proteomic and metabolomic changes initiated by tumor priming to determine the mechanisms of action of INKmune TM Clinical evaluation Four patients have been treated with INKmune TM and their characteristics are presented in table 1. Subjects each received three consecutive i.v. infusions of 1x10 8 INKmune TM over three weeks. Drug was supplied cryopreserved at - 80 o C, thawed at the patient bedside and administered via a blood “giving set”. Patients did not receive any conditioning chemotherapy . Patients were followed for 4 months with measurement of NK cell activation, lytic function against K562 and Raji cells and peripheral blood serum cytokines Proteomics & Metabolomics Peripheral blood NK cells were isolated from health donors and and cultured o/n with INKmune TM or a combination of IL - 2 (200IU/ml) IL - 12 (10 ng/ml) /IL - 15 (50 ng/ml) and IL - 18 (50 ng/ml). Proteome - wide protein profiling was carried out using a protein quantification workflow (HRM, Biognosys ) and liquid chromatography with tandem mass spectrometry (LC - MS/MS). Glycolysis and mitochondrial resporation were measured by oxygen consumption rate and extracellular acidification rate by Seahorse XF analyzer. INKmune TM infusions are well tolerated, can be given without chemotherapy conditioning in an out - patient setting and have been associated with prolonged in vivo NK activation and clinical improvement INKmune TM generates ml - NK cells with enhanced metabolism, improved mitochondrial fitness and lytic function m.lowdell@inmunebio.com www.inmunebio.com K ORCHARD 3 , H ARELLANO - BALLESTERO 1 , A ZUBIAK 1 , C DALLY 3 , D RICHARDSON 3 , R TORRANCE 1 , T EALES 1 , D PEPPA 4 , M SABRY 1 , 2 MW LOWDELL 1 , 2 * 1Department of Haematology, University College London, London, United Kingdom. 2INmuneBio Inc., Boca Ratan, Florida, USA 3Department of Haematology, University Hospital Southampton, Southampton, United Kingdom 4Department of Immunology, University College London, London, United Kingdom. In Vivo Generation of Memory - like NK Cells for the Treatment of AML and Myelodysplastic Syndrome; Early Clinical Applications of INKmune TM INTRODUCTION AIMS METHOD CONCLUSIONS CONTACT INFORMATION RESULTS rNK LAK - 15 CIML - NK INKMUNE - NK INKMUNE TM INDUCES PROTEINS ASSOCIATED WITH ENHANCED FUNCTION & SURVIVAL Proteins significantly increased in TpNK cf CIML - NK INKMUNE TM ENHANCES NK METABOLISM INKmune TM upregulates Mitochondrial survival proteins INKMUNE TM GENERATES ML - NK PHENOTYPE 1. North et al 2007 Journal of Immunology; 178:85 - 94. 2. Katodritou et al 2011 Am J Hematology ; 86:967 - 973 3. Sabry et al 2011 J.Immunology ; 187:6227 - 6234. 4. Tsirogianni et al 2019 . Leuk Lymphoma. 2019 Apr 5:1 - 7. doi : 10.1080/10428194.2019.1581935. 5. Sabry et al 2019 PLoS One. 2019 Jun 26;14(6):e0218674. doi : 10.1371/journal.pone.0218674 REFERENCES REFERENCES INKMUNE TM ACTIVATES NK IN VIVO WITH SUSTAINED ACTIVATION FOR >100 DAYS INKMUNE TM GENERATES ML - NK IN VIVO WITH ENHANCED LYTIC FUNCTION INKMUNE TM TREATMENT LEADS TO SUSTAINED CHANGES IN SYSTEMIC CYTOKINES Azacitidene x19